Use of Rituximab in Combination with Conventional Chemotherapy for the Treatment of Non-Hodgkin's Lymphoma of the Head and Neck

In Vivo

Volumn 23, Issue 3, 2009, Pages 475-478

  Manolopoulos, Leonidas ^a   Gomatos, Ilias P ^a   Leandros, Emmanuel ^a   Alevizos, Leonidas ^a   Georgiou, Natasa ^a   Giotakis, John ^a   Ferekidis, Eleutherios ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

CFhemotherapy; Head and neck; Lymphoma; Rituximab; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ALLOPATHY; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; HEAD AND NECK CANCER; HEART DISEASE; HUMAN; INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

EID: 67649746295     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Coiffier B: Non-Hodgkin's lymphomas. In: Textbook of medical oncology. Cavalli F, Hansen HH, Kaye SB (eds.). London, Martin Dunitz, pp. 265-287, 1997.
2. Gospodarowicz MK and Sutcliffe SB: The extranodal lymphomas. Seniin Radiat Oncol 5: 281-300, 1995.
3. Lawrence TS, Urba WJ, Steinberg SM, Sundeen JT, Cossman J, Young RC and Glatstein E: Retrospective analysis of stage I and II idolent lymphomas at the National Cancer Institute. Tnt J Radiat Oncol Biol Phys 14: 417-424, 1998.
4. Longo DL, DeVita VT Jr, Jaffe ES, Mauch P and Urba WJ: Lymphocytic lymphomas. In: Cancer: principles and practice of oncology, vol. 2. DeVita VT, Jr Hellman S, Rosenberg SA (eds.). Philadelphia, J.B. Lippincott Co., pp. 1859-1927, 1993,
5. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W and Lowenberg B: Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 13: 2530-2539, 1995.
6. Fisher RI, Gaynor ER, Dahlberg 5, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr and Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hondgkin's lymphoma. N Engl J Med 328: 1002-1006, 1993.
7. Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PN and Wilson HE: Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4: 295-305, 1986.
8. Maloney DG: Mechanism of action of rituximab. Anticancer Drugs 12: 1-4, 2001.
9. Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fe receptors modulate in vivo cytoxicity against tumour targets. Nat Med 6: 443-446, 2000.
10. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N and Anderson DR: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD2O. Blood 83: 435-445, 1994.
11. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T and Levy R: IDEC-C2B8 (rituximab) anti-CD2O monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195, 1997.
12. McLaughlin P, Grillo-I,.dpez AJ, Link BK, Levy R, Czuczman MS. Williams ME, Heyman4vlR, Bence-Bruckler I, White CA, Cabanillas F, Jam V, Ho AD, Lister 3, Wey K, Shen D and Dallaire BK: Rituximab chimeric anti-CD2O monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833, 1998.
13. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V and Reyes F: Rituximab (anti-CD2O monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92: 1927-1932, 1998.
14. Foran JM, Rohatiner AZ, Cunningham D, Popescu RA, SolalCeligny P, Ghielmini M, Coiffier B, Johnson PW, Gisselbrecht C, Reyes F, Radford JA, Bessell EM, Souleau B, Benzohra A and Lister TA: European phase II study of rituxiniab (chimeric anti-CD2O monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantlecell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18: 3 17-324, 2000.
15. Czuczman MS. Grillo-LOpez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B and Varns C: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD2O monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17: 268-276, 1999.
16. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kuokel LA and Fisher RI: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 19: 389-397, 2001.
17. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P. Van Den Neste E, Salles G, Gaulard P. Reyes F, Lederlin P and Gisselbrecht C: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N EngI J Med 346: 235- 242,2002.
18. Jacobs C and Hoope RT: Non Hodgkin's of the head and neck extranodal sites. Tnt J Radiat Oncol Biol Phys 11: 357-364, 1985.
19. Jacobs C, Weiss L and Hoope RT: The management of extranodal head and neck lymphomas. Arch Otolaryngol Head Neck Surg 112: 654-658, 1986.
20. Saul SH and Kapadia SB: Primary lymphoma of Waldeyer's ring. Clinicopathologic study of 68 cases. Cancer 56: 157-166, 1985.
21. Banfi A, Bonadonna G, Carnevali G, Malinari R, Montfardini S and Salvini E: Lymphoreticular sarcomas with primary involvement of Waldeyer's ring. Clinical evaluation. Cancer 26: 341-351, 1970.
22. Aviles A, Delgado S, Ruiz H, de Ia Torre A, Guzman R and Talavera A: Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Eur 3 Cancer B Oral Oncol 32B: 19-23, 1996.
23. Zucca E,/Roggero E, Bertoni F, Conconi A and Cavalli F: Primary extranodal non-Hodgkin's lymphoma. Part 2: head and neck, central nervous system and other less common sites. Ann Oncol 10: 1023-1033, 1999.